Survival Outcomes With Cadonilimab Versus PD-(L)1 Therapy in Front-Line Gastric Cancer: A Network Meta-Analysis.
The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk-benefit profile for patients with low PD-L1 expression remains unclear in front-line treatment of HER2-negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD-(L)1 therapy. The first PD-1/CTLA-4 bispecific antibody (BsAb), cadonilimab, has been approved, but it is unknown if it can extend the PD-(L)1 regimen to lower PD-L1 patients.
The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk-benefit profile for patients with low PD-L1 expression remains unclear in front-line treatment of HER2-negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD-(L)1 therapy. The first PD-1/CTLA-4 bispecific antibody (BsAb), cadonilimab, has been approved, but it is unknown if it can extend the PD-(L)1 regimen to lower PD-L1 patients.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Cancer Rep (Hoboken)
Why it surfaced
Matched watchlist topic 'Novel therapeutics: immunotherapy, CAR-T, targeted therapy'. Study design: Randomized Controlled Trial (inferred). Score: 9/10 (N:2, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.